Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of post-transplant cyclophosphamide after HLA 6-8/8 matched peripheral blood stem cell transplantation
jRCTs011190009Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Mar 2020
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, tacrolimus and mycophenolate mofetil in hematopoietic malignancies, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Incidence of grade III-IV acute graft-versus-host disease at 100 days. Started Mar 2020; status: completed.
02
Drugs
cyclophosphamidetacrolimusmycophenolate mofetil
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on jRCTs011190009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011190009.